HPV seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected MSM

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2455-2461

  Mooij, Sofie H ^a,b   Landén, Olivia ^a   Van Der Klis, Fiona R M ^c   Van Der Sande, Marianne A B ^c,d   De Melker, Hester E ^c   Xiridou, Maria ^c   Van Eeden, Arne ^e,g   Heijman, Titia ^a   Speksnijder, Arjen G C L ^a   Snijders, Peter J F ^f   Van Der Loeff, Maarten F Schim ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Jan Van Goyen Medical Center   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g DC Klinieken Oud Zuid ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY BLOOD LEVEL; ANUS DISEASE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PENIS DISEASE; SEROCONVERSION; SEROPREVALENCE; VIRUS LOAD; ANAL CANAL; GENETICS; MALE HOMOSEXUALITY; PAPILLOMAVIRIDAE; PENIS; RISK FACTOR; VIROLOGY;

ADULT; ANAL CANAL; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENIS; RISK FACTORS;

EID: 84920126786     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0199     Document Type: Article

References (33)

1. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjosé S, Kjaer SK, et al. Epidemiology ofhuman papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26 Suppl 10:K17-28.
2. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjosé S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 Suppl 10:K1-16.
3. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011;377:932-40.
4. Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer 2010;5:19.
5. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
6. Edelstein ZR, Carter JJ, Garg R, Winer RL, Feng Q, Galloway DA, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis 2011;204:209-16.
7. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200:1059-67.
8. Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health 2012;50:110-31.
9. Mollers M, Vossen JM, Scherpenisse M, van der Klis FR, Meijer CJ, de Melker HE. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013;85:1379-85.
10. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-6.
11. Lu B, Viscidi RP, Lee JH,WuY, Villa LL, Lazcano-Ponce E, et al.Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev 2011;20:990-1002.
12. Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, et al. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev 2012;21:1542-6.
13. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
14. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123-38.
15. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 2011;48:540-52.
16. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009;23:2337-45.
17. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012;13:487-500.
18. Jansen IA, Geskus RB, Davidovich U, Jurriaans S, Coutinho RA, Prins M, et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS 2011;25:493-501.
19. Heijman RL, Stolte IG, Thiesbrummel HF, van LE, Coutinho RA, Fennema JS, et al. Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic. Sex Transm Infect 2009;85:249-55.
20. Van Aar F,Mooij SH, van der Sande MA,Speksnijder AG, Stolte IG,Meijer CJ, et al. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS 2013;27:2921-31.
21. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, de Melker HE, Meijer CJ, et al. Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 2012;30:6686-93.
22. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998;221:35-41.
23. Van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292-8.
24. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, Massad LS, et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010;19:159-69.
25. Mooij SH, van der Klis FR, van der Sande MA, Schepp RM, Speksnijder AG, Bogaards JA, et al. Seroepidemiology of high-risk HPV in HIVnegative and HIV-infected MSM: the H2M study. Cancer Epidemiol Biomarkers Prev 2013;22:1698-708.
26. Hagensee ME, Kiviat N, Critchlow CW, Hawes SE, Kuypers J, Holte S, et al. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 1997;176:625-31.
27. Vriend HJ, Bogaards JA, van der Klis FR, Scherpenisse M, Boot HJ, King AJ, et al. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS ONE 2013;8:e60696.
28. Heiligenberg M, Alberts CJ, Waterboer T, Speksnijder AG, de Vries HJ, Pawlita M, et al. Route of sexual exposure is independently associated with seropositivity to HPV-16 and HPV-18 among clients of an STI clinic in the Netherlands. J Infect Dis 2013;208:1081-5.
29. de Gruijl TD, Bontkes HJ, Walboomers JM, Schiller JT, Stukart MJ, Groot BS, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630-8.
30. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011;121:4593-9.
31. Faust H, Jelen MM, Poljak M, Klavs I, Ucakar V, Dillner J. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. J Clin Virol 2013;56:336-41.
32. Scherpenisse M, Schepp RM, Mollers M, Mooij SH, Meijer CJ, Berbers GA, et al. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol 2013;20:1329-32.
33. Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS ONE 2013;8:e74797.